30 closest matches · ranked by relevance
Cancer Metastatic to Brain · Brain Metastases, Adult
Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
Cancer
Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT
Intraabdominal Cancers (Various Types)
Primary: Maximum Tolerated Dose (MTD) of RENCA Macrobeads — NA RENCA Macrobeads/kg
Advanced Malignant Neoplasm · Metastatic Malignant Neoplasm · Unresectable Malignant Neoplasm
Primary: Number of Participants With Dose-Limiting Toxicity — 0; 1; 0; 0 Participants
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Gastric Adenocarcinoma · Esophageal Cancer · Hepatocellular Carcinoma
Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…
Malignant Melanoma · Head and Neck Cancer
Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Human Papilloma Virus · Cervical Cancer · Oropharyngeal Cancer
Primary: Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response — 31; 7.7 percentage of participants
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Infectious Disease · Cancer · Coronavirus Infection
Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Advanced Cancer
Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)
Adenocarcinoma · Colorectal Cancer · Ovarian Cancer
Primary: Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease in the Ovarian Cancer and Breast Cancer Cohorts…
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Non-small Cell Lung Cancer
Primary: To Describe the Pattern of CTCs Before and After Definitive Radiotherapy for Each Treatment Stratum — 3.9; 9.1; 9.1; 9.1 CTCs/mL
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Cancer
Primary: Number of Participants With Positive Viral Infection — 19; 197; 71; 34 Participants
Myelodysplastic Syndrome (MDS) · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Number of Participants Who Experienced Inducing or Boosting of a Cellular Immune Response — 5; 2 participants
Advanced B-cell Lymphoid Malignancies
Primary: Total Number of Adverse Events. — 2 Adverse events
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg